Magenta Therapeutics Inc
Change company Symbol lookup
Select an option...
MGTA Magenta Therapeutics Inc
PT Pintec Technology Holdings Ltd
CLSH CLS Holdings USA Inc
UN Unilever NV
AWK American Water Works Company Inc
AEG Aegon NV
SBUX Starbucks Corp
PFE Pfizer Inc
CRON Cronos Group Inc
CVSI CV Sciences Inc
Go

Health Care : Biotechnology | Company profile

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.

Closing Price
$18.27
Day's Change
0.44 (2.47%)
Bid
--
Ask
--
B/A Size
--
Day's High
18.27
Day's Low
16.95
Volume
(Light)
Volume:
199,081

10-day average volume:
396,664
199,081

UPDATE: Aurora Cannabis stock fails to hold gains after company unveils plan to buy Mexican partner

8:23 am ET December 11, 2018 (MarketWatch)
Print

By Ciara Linnane, MarketWatch

Rest of sector mixed after rally sparked by Altria investment in Cronos

Just days after Aurora Cannabis Inc. announced a supply deal with Mexico's Farmacias Magistrales SA, the Canadian cannabis company said it has entered a letter of intent to buy all of the company's outstanding shares in an all-stock deal.

Farmacias is Mexico's first and, for now, only federally licensed importer of raw materials containing THC, the psychoactive ingredient in cannabis, Aurora (ACB.T) (ACB.T) said in a statement. The company has the licenses and facilities to store and distribute medical products with more than 1% THC.

The deal "firmly establishes Aurora's first-mover advantage in one of the world's most populous countries, where more than 130 million people will have federally legal access to a range of Aurora's non-flower medical cannabis products containing THC," said the statement. Aurora also have operations in Colombia and Uruguay.

Farmacias has about 80,000 retail outlets for selling CBD products and 500 pharmacies and hospitals to sell THC products. Aurora will pay for the deal with stock based on a valuation of the proforma revenue distribution projections of Farmacias.

Farmacias will use imported THC and CBD concentrates to make cannabis oil products for the medical market. over time, it will expand to include products such as capsules, topical solutions and sprays and other delivery formats.

See also:How dangerous are marijuana stocks? Even a company with notable achievements has plunged (http://www.marketwatch.com/story/how-dangerous-are-marijuana-stocks-even-a-company-with-notable-achievements-has-plunged-2018-11-30)

"Integrating Farmacias with our operations in Canada and Latin America will not only accelerate growth, it will build substantial long-term shareholder value," Aurora Chief Executive Terry Booth said in the statement.

Canadian-listed Aurora shares rose initially on the news, before reversing their gains to trade lower in early afternoon trade.

The rest of the cannabis sector was mixed. Cronos Group Inc. (CRON.T) shares rose 1.3%, after earlier shedding some of the gains made Friday on the news that tobacco giant Altria Inc. (http://www.marketwatch.com/story/cannabis-stock-cronos-soars-24-as-altria-takes-major-stake-2018-12-07)(MO) was investing $1.8 billion in the company (http://www.marketwatch.com/story/cannabis-stock-cronos-soars-24-as-altria-takes-major-stake-2018-12-07). Cronos CEO Mike Gorenstein told MarketWatch that the deal was just the start for his company and the industry.

Don't miss:Canada's struggle to supply legal weed described as 'national shortage' that could last months (http://www.marketwatch.com/story/canadas-struggle-to-supply-legal-weed-described-as-national-shortage-that-could-last-months-2018-11-26)

"We just got a new partner and now resources -- but beyond that the network and support [Altria] can offer -- being able to have that experience. It's an alignment and a partnership but it's not like the deal is over. We're all very, very excited about the beginning, and we can now go and do the things we want to do," he said in an interview.

Read more:Cronos CEO: $1.8 billion from Big Tobacco is just a beginning for cannabis industry (http://www.marketwatch.com/story/cronos-ceo-says-altria-investment-is-just-the-beginning-2018-12-07)

Read now:Marijuana producer Aphria's stock rebounds after second short-seller report (http://www.marketwatch.com/story/marijuana-producer-aphrias-stock-rebounds-after-second-short-seller-report-2018-12-06)

Cormark Securities upgraded Cronos to buy from market perform on Monday and raised its stock price target to $17 from $10, or about 42% above its current trading level.

"We like the collaborative potential between the companies and see an immediate ability for CRON to benefit from Altria's existing pre-roll and device technology," analyst Jesse Pytlak wrote in a note.

Elsewhere in the sector, Canopy Growth Corp. (WEED.T) (WEED.T) shares were down about 0.6%, shedding early gains made after a bullish note from Benchmark. Analysts said they attended the company's analyst day last week and toured its Smiths Falls, Ontario facilities.

"We remain confident WEED can be a share winner in the rapidly emerging cannabis market; paramount attributes include vision, execution and product & brand development," wrote analyst Mike Hickey.

Hickey is expecting the 2018 Farm Bill to be approved by year-end, effectively legalizing CBD, or cannabidiol, the non-psychoactive ingredient in cannabis, which is used in a variety of medical products. The bill would remove industrial hemp from the government's list of controlled substances and is expected to open the market for rapid expansion.

"We believe WEED will invest meaningful capital into the U.S. after CBD legalization and leverage the Constellation Brands manufacturing profile to create CBD beverages; we expect a deployment strategy already firmly in place and will provide for near term growth," Hickey wrote.

Corona beer maker Constellation Brands (STZ) has invested $4 billion in Canopy Growth, a move expected to be followed by other big drinks companies.

Tilray Inc. shares were down 2.9%, Aphria Inc. (APHA.T) was up 6.4% and Hexo Corp. (HEXO.T) was down 4%. Aleafia Health Inc. (ALEF.V) shares fell 9% and Green Organic Dutchman Holdings Inc.(TGOD.T)(TGOD.T) was down 4%.

The ETFMG Alternative Harvest ETF (MJ) was down 2% and the Horizons Marijuana Life Sciences ETF was down 1%.

The S&P 500 was down 0.4% and the Dow Jones Industrial Average was down 0.5%.

See now:To read all of MarketWatch's coverage of the nascent cannabis industry, click here. (http://www.marketwatch.com/topics/columns/cannabis-watch)

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 11, 2018 08:23 ET (13:23 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.